Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan T Vogl

Showing results (11-20 of 73) with videos related to

Pageof 8
Sort By:
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 6, 2005
Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexaroteneDonald E Tsai, Nicole A Aqui, Dan T Vogl, et al.
Leukemia & Lymphoma|February 1, 2017
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myelomaDan T Vogl, Thomas G Martin, Ravi Vij, et al.
Leukemia & Lymphoma|May 10, 2007
Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen casesHimisha Patel, Dan T Vogl, Nicole Aqui, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Neutrophil extracellular traps promote tumor chemoresistance to anthracyclinesCindy Lin, Sarah E Herlihy, Marina Li, et al.
The Lancet. Haematology|December 22, 2015
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyScott F Huntington, Brendan M Weiss, Dan T Vogl, et al.
Cancer|April 13, 2021
A unique window of opportunity for practical reform of cancer clinical trialsDan T Vogl, Vicki Sallée, Maria C Hendricks, et al.
Leukemia & Lymphoma|August 20, 2005
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiationDan T Vogl, Eli Glatstein, Joseph R Carver, et al.
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
JAMA Oncology|December 30, 2017
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysisAdam J Waxman, Suparna Clasen, Wei-Ting Hwang, et al.
European Journal of Haematology|December 5, 2022
Progressive multifocal leukoencephalopathy in multiple myelomaBrian W Hoeynck, Adam D Cohen, Edward A Stadtmauer, et al.
Pageof 8

Showing results (11-20 of 73) with videos related to

Sort By:
Pageof 8
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|July 6, 2005
Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexaroteneDonald E Tsai, Nicole A Aqui, Dan T Vogl, et al.
Leukemia & Lymphoma|February 1, 2017
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myelomaDan T Vogl, Thomas G Martin, Ravi Vij, et al.
Leukemia & Lymphoma|May 10, 2007
Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen casesHimisha Patel, Dan T Vogl, Nicole Aqui, et al.
Biorxiv : the Preprint Server for Biology|November 28, 2024
Neutrophil extracellular traps promote tumor chemoresistance to anthracyclinesCindy Lin, Sarah E Herlihy, Marina Li, et al.
The Lancet. Haematology|December 22, 2015
Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyScott F Huntington, Brendan M Weiss, Dan T Vogl, et al.
Cancer|April 13, 2021
A unique window of opportunity for practical reform of cancer clinical trialsDan T Vogl, Vicki Sallée, Maria C Hendricks, et al.
Leukemia & Lymphoma|August 20, 2005
Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiationDan T Vogl, Eli Glatstein, Joseph R Carver, et al.
British Journal of Haematology|September 4, 2009
Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myelomaDan T Vogl, Edward A Stadtmauer, Paul G Richardson, et al.
JAMA Oncology|December 30, 2017
Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysisAdam J Waxman, Suparna Clasen, Wei-Ting Hwang, et al.
European Journal of Haematology|December 5, 2022
Progressive multifocal leukoencephalopathy in multiple myelomaBrian W Hoeynck, Adam D Cohen, Edward A Stadtmauer, et al.
Pageof 8